Detalhe da pesquisa
1.
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
Blood
; 2024 Mar 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38484137
2.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Blood
; 143(16): 1565-1575, 2024 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38252906
3.
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Blood
; 142(16): 1359-1370, 2023 Oct 19.
Artigo
Inglês
| MEDLINE | ID: mdl-37339586
4.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Blood
; 142(7): 621-628, 2023 08 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37319432
5.
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Blood
; 142(10): 878-886, 2023 09 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37319435
6.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 141(19): 2307-2315, 2023 05 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36821768
7.
Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.
Cancer
; 130(12): 2205-2214, 2024 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38358333
8.
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Blood
; 140(25): 2697-2708, 2022 12 22.
Artigo
Inglês
| MEDLINE | ID: mdl-35700381
9.
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Blood
; 139(25): 3605-3616, 2022 06 23.
Artigo
Inglês
| MEDLINE | ID: mdl-35316328
10.
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Blood
; 139(9): 1330-1339, 2022 03 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34570879
11.
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
Blood
; 140(19): 2024-2036, 2022 11 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35914220
12.
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Haematologica
; 109(4): 1194-1205, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37767550
13.
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Haematologica
; 109(2): 533-542, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37470137
14.
Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Curr Treat Options Oncol
; 25(5): 659-678, 2024 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38656685
15.
Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
Br J Haematol
; 202(4): 771-775, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37188351
16.
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Br J Haematol
; 200(1): 54-63, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36120837
17.
How I incorporate novel agents into the treatment of classical Hodgkin lymphoma.
Blood
; 138(7): 520-530, 2021 08 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33889927
18.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Blood
; 138(6): 427-438, 2021 08 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33827139
19.
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma.
Haematologica
; 108(8): 2167-2177, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36632739
20.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Haematologica
; 108(1): 98-109, 2023 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35833303